Lilly’s lepodisiran shows 94% reduction in lipoprotein(a), offering hope for cardiovascular risk management

Lilly’s lepodisiran slashed lipoprotein(a) by 94% in a Phase 2 trial. See how this breakthrough could change cardiovascular disease treatment. Read More